SLU-PP-332 is a synthetic small-molecule research compound that activates the estrogen-related receptors (ERRs)—particularly ERRα, and also ERRβ and ERRγ. It has attracted attention because researchers describe it as an “exercise mimetic”: it can activate some of the molecular programs normally stimulated by aerobic exercise.
Importantly, SLU-PP-332 is not estrogen, not a peptide, and not an approved drug or dietary supplement. The evidence remains primarily from cell and animal studies, so its effects and safety in humans have not been established.
1. Basic identity
| Property | Description |
| Name | SLU-PP-332 |
| Type | Synthetic small molecule |
| Pharmacological class | Estrogen-related receptor (ERR) agonist |
| Targets | ERRα, ERRβ, ERRγ |
| Strongest activity | ERRα |
| Saint Louis | University/Burris laboratory research |
| Main research area | Exercise biology, mitochondrial metabolism, obesity and metabolic disease |
| Development stage | Preclinical research |
| Human clinical status | No established human efficacy/safety data |
The compound was developed as a chemical tool for studying ERR signaling and was reported in 2023 to activate all three ERR subtypes, with particularly strong ERRα activity.
2. How does it work?
ERRs are orphan nuclear receptors that regulate genes involved in energy metabolism and mitochondrial function.
A simplified pathway is:
SLU-PP-332 → ERRα/β/γ activation → transcription of oxidative-metabolism genes → increased mitochondrial activity → greater fatty-acid oxidation and energy expenditure
In skeletal-muscle cells, SLU-PP-332 increased mitochondrial function and cellular respiration. In mice, it increased oxidative type-IIa muscle fibers and improved exercise endurance.
This is why it is often called an exercise mimetic. However, this term should not be interpreted as meaning that the compound reproduces all the physiological benefits of actual exercise.
3. What has been observed in animals?
Research in mice has reported several interesting effects:
- ↑ mitochondrial oxidative capacity
- ↑ fatty-acid oxidation
- ↑ energy expenditure
- ↑ oxidative skeletal-muscle fibers
- ↑ exercise endurance
- ↓ fat accumulation
- improved insulin sensitivity
- improvements in some features of metabolic syndrome
For example, in obese mouse models, SLU-PP-332 increased resting energy expenditure and fatty-acid oxidation and was associated with reduced adiposity and improved glucose tolerance.
4. Why is it interesting for longevity/metabolic research?
SLU-PP-332 is particularly interesting because ERR signaling sits at the intersection of mitochondrial function, skeletal-muscle metabolism and exercise adaptation.
Researchers are investigating whether pharmacologically activating this pathway could eventually have applications in conditions such as:
obesity → metabolic syndrome → insulin resistance → reduced muscle function → age-associated mitochondrial dysfunction
A 2026 chemical-optimization study further examined the structural features responsible for SLU-PP-332’s ERR activity and sought compounds with improved potency and metabolic stability.
5. Is it a weight-loss drug?
Not currently.
The mouse results are promising, but it would be incorrect to conclude that SLU-PP-332 is an established human weight-loss treatment. There is currently no clinical evidence establishing an appropriate human dose, long-term safety, or efficacy.
So the distinction is:
Mouse research: promising metabolic and endurance effects
Human medicine: not established
6. SLU-PP-332 vs. actual exercise
| Feature | SLU-PP-332 | Aerobic exercise |
| Activates ERR pathway | ✓ | ✓ |
| Increases mitochondrial activity | ✓ in research models | ✓ |
| Promotes oxidative muscle phenotype | ✓ in mice | ✓ |
| Increases endurance | ✓ in mice | ✓ |
| Burns more fatty acids | ✓ in mice | ✓ |
| Improves cardiovascular fitness | Not established | ✓ |
| Broad systemic benefits | Not established | ✓ |
| Proven safe long-term in humans | No | Yes, when appropriately performed |
Bottom line: SLU-PP-332 is best understood as an experimental ERRα/β/γ agonist and pharmacological exercise-mimetic research tool, rather than a supplement or established medicine. Its most interesting property is its ability to switch on transcriptional programs associated with mitochondrial oxidative metabolism and aerobic exercise, producing increased endurance and favorable metabolic changes in mice.
If you’re studying SLU-PP-332 in depth, the next useful topics are its chemical structure, mechanism of action, synthesis, pharmacokinetics, effects on mitochondria/fat burning, side effects and safety, and comparison with SLU-PP-915 and 5-Amino-1MQ.